Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001805097
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer Enliven Therapeutics, Inc.

SEC File Number 001-39247

6200 LOOKOUT ROAD

Address of Issuer

BOULDER
COLORADO

80301

Phone 720-647-8519

Name of Person for Whose Account the Securities are To Be Sold

Ballal Rahul D.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	20000	350800.00	41200000	03/20/2024	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	from Whom	this	Donor	Securities	Payment	Payment *
	-	Transaction	Acquired		Acquired	Acquired		

			Gift?		
Common	01/28/2022 Stock Options Grant	Enliven Therapeutics, Inc.		12316	01/28/2022 N/A
Common	01/28/2022 Stock Option Grant	Enliven Therapeutics, Inc.		2052	01/28/2022 N/A
Common	01/28/2022 Stock Options Grant	Enliven Therapeutics, Inc.		2053	01/28/2022 N/A
Common	10/19/2018 Stock Option Grant	Enliven Therapeutics, Inc.		3579	10/19/2018 N/A

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

a

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated

10/19/2023, and all representations regarding material non-public information were made as of

the adoption of the plan.

Date of Notice 03/20/2024

Date of Plan Adoption or Giving

of Instruction, If Relying on 10/19/2023

Rule 10b5-1

ATTENTION:

Remarks

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Rahul Ballal

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)